Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: one-year results of a randomized clinical trial.
Amir FaramarziHamed AbbasiSepehr FeiziYasaman HadiAmir A AzariFarid KarimianMohammad Reza JafarinasabBahareh KheiriPublished in: Eye (London, England) (2021)
Topical 0.03% tacrolimus was as effective as systemic MMF as adjuncts to topical and systemic corticosteroids in reducing endothelial graft rejection with 12 months follow up after repeat keratoplasty.
Keyphrases